Pubfacts - Scientific Publication Data
  • Categories
  • |
  • Journals
  • |
  • Authors
  • Login
  • Categories
  • Journals

Search Our Scientific Publications & Authors

Publications
  • Publications
  • Authors
find publications by category +
Translate page:

Combined inhibition of PD-1/PD-L1, Lag-3, and Tim-3 axes augments antitumor immunity in gastric cancer-T cell coculture models.

Authors:
Kosaku Mimura Ley-Fang Kua Jin-Fen Xiao Bernadette Reyna Asuncion Yuko Nakayama Nicholas Syn Zul Fazreen Richie Soong Koji Kono Wei-Peng Yong

Gastric Cancer 2021 Feb 20. Epub 2021 Feb 20.

Department of Haematology-Oncology, National University Health System (S) Pte Ltd, Level 7, NUHS Tower Block, 1E Kent Ridge Road, Singapore, 119228, Singapore.

Background: Immunotherapy targeting PD-1 provides a limited survival benefit in patients with unresectable advanced or recurrent gastric cancer (GC). Beside PD-L1, the expression of inhibitory ligands such as CEACAM-1 and LSECtin on GC cells account for this limitation. Here we assessed their expression and immune suppressive effect in GC patients.

Methods: Using multiplexed immunohistochemistry staining, we evaluated the distribution of different inhibitory ligands, including PD-L1, CEACAM-1, LSECtin, and MHC class II, in 365 GC patients. We analyzed their correlations and overall survival (OS) based on the expression of each inhibitory ligand and the independent prognostic factors that affect OS. Subsequently, we evaluated the additive effect of anti-PD-1 mAb or anti-PD-L1 mAb with/without anti-Lag-3 mAb with/without anti-Tim-3 mAb in cytotoxic assay using tumor-antigen specific CTL clones against GC cell lines.

Results: Co-expression of the inhibitory ligands for PD-1, Tim-3, and Lag-3 was observed in the largest proportion (34.7%). CEACAM-1, LSECtin, and MHC class II expression showed significant correlation with PD-L1 expression and OS. Multivariable analysis demonstrated that CEACAM-1 low is an independent prognostic factor. Furthermore, combining dual and triple ICIs yielded additive effect on cytotoxicity of CTL clones against each immune inhibitory ligand positive GC cell lines.

Conclusions: Our findings suggested that the expression of inhibitory ligands for Tim-3 and Lag-3 on GC cells serve as potential biomarkers to predict the response to anti-PD-1 therapy and the combinatorial immunotherapy with ICIs targeting for PD-1, Tim-3, and Lag-3 has a therapeutic potential for GC patients.

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10120-020-01151-8DOI Listing
February 2021

Publication Analysis

Top Keywords

inhibitory ligands
16
expression inhibitory
12
tim-3 lag-3
12
ceacam-1 lsectin
12
pd-l1 expression
8
inhibitory ligand
8
lsectin mhc
8
targeting pd-1
8
ctl clones
8
independent prognostic
8
pd-1 tim-3
8
mhc class
8
inhibitory
6
expression
6
observed largest
4
specific ctl
4
assay tumor-antigen
4
lag-3 observed
4
tumor-antigen specific
4
cell linesresults
4

Keyword Occurance

Similar Publications

Potent Toxic Effects of Taroxaz-104 on the Replication of SARS-CoV-2 Particles.

Authors:
Amgad M Rabie

Chem Biol Interact 2021 Apr 19:109480. Epub 2021 Apr 19.

Dr. Amgad Rabie's Research Lab. for Drug Discovery (DARLD), Mansoura, Egypt; Pharmaceutical Organic Chemistry Department, Faculty of Pharmacy, Mansoura University, Mansoura, 35516, Egypt. Electronic address:

Polyphenolics and 1,3,4-oxadiazoles are two of the most potent bioactive classes of compounds in medicinal chemistry, since both are known for their diverse pharmacological activities in humans. One of their prominent activities is the antimicrobial/antiviral activities, which are much apparent when the key functional structural moieties of both of them meet into the same compounds. The current COVID-19 pandemic motivated us to computationally screen and evaluate our library of previously-synthesized 2-(3,4,5-trihydroxyphenyl)-1,3,4-oxadiazoles against the major SARS-CoV-2 protein targets. Read More

View Article and Full-Text PDF
April 2021
Similar Publications

Identification and expression analysis of group II C-type lectin domain containing receptors in grass carp Ctenopharyngodon idella.

Authors:
Zhao Jia Junya Wang Kangyong Chen Qin Zhang Zhaosheng Sun Zeinab Hassan Hao Feng Jun Zou

Gene 2021 Apr 18:145668. Epub 2021 Apr 18.

Key Laboratory of Exploration and Utilization of Aquatic Genetic Resources, Ministry of Education, Shanghai Ocean University, Shanghai, 201306, China; International Research Center for Marine Biosciences at Shanghai Ocean University, Ministry of Science and Technology, China; National Demonstration Center for Experimental Fisheries Science Education, Shanghai Ocean University, Shanghai, China; Laboratory for Marine Biology and Biotechnology, Qingdao National Laboratory for Marine Science and Technology, Qingdao, China. Electronic address:

Group II C-type lectin domain (CTLD) containing receptors belong to a large family of pattern recognition receptors which mainly act on the innate immunity. They are structurally related and consist of a cytoplasmic immunoreceptor tyrosine-based inhibitory motif (ITIM) and a single extracellular CTLD. Although they have been described in teleost fish, their involvement in immune responses is not well understood. Read More

View Article and Full-Text PDF
April 2021
Similar Publications

Molecular docking and ADMET studies of and isolates as potential anti-viral drugs for Covid-19.

Authors:
Peter Ifeoluwa Adegbola Banjo Semire Olumide Samuel Fadahunsi Aanuoluwa Eunice Adegoke

Virusdisease 2021 Apr 10:1-13. Epub 2021 Apr 10.

Department of Pure and Applied Chemistry, Faculty of Pure and Applied Sciences, Ladoke Akintola University of Technology, Ogbomoso, Nigeria.

Plants are repository of important constituents with proven efficacy against many human diseases including viral diseases. The antiviral activity of many plants including and has been reported. The novel coronavirus disease is no exception among viral diseases in which plant compounds could serve as potent antagonist. Read More

View Article and Full-Text PDF
April 2021
Similar Publications

Role of Polymorphisms of NKG2D Receptor and Its Ligands in Acute Myeloid Leukemia and Human Stem Cell Transplantation.

Authors:
Alena Machuldova Monika Holubova Valentina S Caputo Miroslava Cedikova Pavel Jindra Lucie Houdova Pavel Pitule

Front Immunol 2021 30;12:651751. Epub 2021 Mar 30.

Laboratory of Tumor Biology and Immunotherapy, Biomedical Center, Faculty of Medicine in Pilsen, Charles University, Pilsen, Czechia.

Natural killer cells possess key regulatory function in various malignant diseases, including acute myeloid leukemia. NK cell activity is driven by signals received through ligands binding activating or inhibitory receptors. Their activity towards elimination of transformed or virally infected cells can be mediated through MICA, MICB and ULBP ligands binding the activating receptor NKG2D. Read More

View Article and Full-Text PDF
March 2021
Similar Publications

Case Report: Combination Therapy With PD-1 Blockade for Acute Myeloid Leukemia After Allogeneic Hematopoietic Stem Cell Transplantation Resulted in Fatal GVHD.

Authors:
Sun Yao Chen Jianlin Qiao Zhuoqing Li Yuhang Hu Jiangwei Hu Guoliang Ning Hongmei Zhang Bin Hu Liangding

Front Immunol 2021 1;12:639217. Epub 2021 Apr 1.

Department of Hematology, The Fifth Medical Center of Chinese People's Liberation Army General Hospital, Beijing, China.

Azacitidine is commonly used in the treatment of relapsed acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) after allogeneic hematopoietic stem cell transplantation (allo-HSCT), but the effectiveness of this monotherapy is still very low. A possible mechanism of resistance to hypomethylating agents (HMAs) is the upregulation of the expression of inhibitory checkpoint receptors and their ligands, making the combination of HMAs and immune checkpoint blockade therapy a rational approach. Although the safety of anti-programmed cell death protein (PD)-1 antibodies for patients with post-allo-HSCT remains a complicated issue, the preliminary clinical result of combining azacitidine with anti-PD-1 antibodies is encouraging; however, the safety and efficacy of this approach need further investigation. Read More

View Article and Full-Text PDF
April 2021
Similar Publications
© 2021 PubFacts.
  • About PubFacts
  • Privacy Policy
  • Sitemap